advanced search

<< Back To Home

Vaccine strategies: optimising outcomes [Special Issue]

Tuesday, 20th of December 2016

Karin Hardt, Paolo Bonanni, Susan King, Jose Ignacio Santos, Mostafa El-Hodhod, Gregory D. Zimet, et al.

Vaccine strategies: optimising outcomes [Special Issue]

Vaccine, 34 (52) (2016), pp. 6691–6699                                    

Vaccine. 2016 Dec 20;34(52):6691-6699. doi: 10.1016/j.vaccine.2016.10.078. Epub 2016 Nov 23.

Vaccine strategies: Optimising outcomes.

Hardt K1, Bonanni P2, King S3, Santos JI4, El-Hodhod M5, Zimet GD6, Preiss S7.

Author information

1GSK Vaccines, Avenue Fleming 20, Parc de la Noire Epine, B-1300 Wavre, Belgium. Electronic address: karin.hardt@gsk.com.

2University of Florence, Department of Health Sciences, Viale GB Morgagni 48, Florence, Italy. Electronic address: paolo.bonanni@unifi.it.

3GSK Vaccines, Avenue Fleming 20, Parc de la Noire Epine, B-1300 Wavre, Belgium. Electronic address: sue.a.king@gsk.com.

4Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico. Electronic address: joseignaciosantos56@gmail.com.

5Ain Shams University, Faculty of Medicine, Pediatrics Department, Cairo, Egypt. Electronic address: mostafaelhodhod@yahoo.com.

6Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: gzimet@iu.edu.

7GSK Vaccines, Avenue Fleming 20, Parc de la Noire Epine, B-1300 Wavre, Belgium. Electronic address: scott.s.preiss@gsk.com.

Abstract below; full text is at http://www.sciencedirect.com/science/article/pii/S0264410X16310301

 

Successful immunisation programmes generally result from high vaccine effectiveness and adequate uptake of vaccines. In the development of new vaccination strategies, the structure and strength of the local healthcare system is a key consideration. In high income countries, existing infrastructures are usually used, while in less developed countries, the capacity for introducing new vaccines may need to be strengthened, particularly for vaccines administered beyond early childhood, such as the measles or human papillomavirus (HPV) vaccine. Reliable immunisation service funding is another important factor and low income countries often need external supplementary sources of finance. Many regions also obtain support in generating an evidence base for vaccination via initiatives created by organisations including World Health Organization (WHO), the Pan American Health Organization (PAHO), the Agence de Médecine Préventive and the Sabin Vaccine Institute. Strong monitoring and surveillance mechanisms are also required. An example is the efficient and low-cost approaches for measuring the impact of the hepatitis B control initiative and evaluating achievement of goals that have been established in the WHO Western Pacific region. A review of implementation strategies reveals differing degrees of success. For example, in the Americas, PAHO advanced a measles-mumps-rubella vaccine strategy, targeting different population groups in mass, catch-up and follow-up vaccination campaigns. This has had much success but coverage data from some parts of the region suggest that children are still not receiving all appropriate vaccines, highlighting problems with local service infrastructures. Stark differences in coverage levels are also observed among high income countries, as is the case with HPV vaccine implementation in the USA versus the UK and Australia, reflecting differences in delivery settings. Experience and research have shown which vaccine strategies work well and the factors that encourage success, which often include strong support from government replicas de relojes suizos and healthcare organisations, as well as tailored, culturally-appropriate local approaches to optimise outcomes.

Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.